Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 6511 | 2.94 |
09:34 ET | 3611 | 2.925 |
09:36 ET | 4165 | 2.935 |
09:38 ET | 2084 | 2.935 |
09:39 ET | 200 | 2.93 |
09:41 ET | 2501 | 2.9 |
09:43 ET | 3011 | 2.89 |
09:45 ET | 2392 | 2.871 |
09:48 ET | 400 | 2.8725 |
09:50 ET | 2024 | 2.88 |
09:52 ET | 1200 | 2.9 |
09:54 ET | 1706 | 2.9 |
09:56 ET | 600 | 2.9 |
09:57 ET | 8785 | 2.875 |
09:59 ET | 14422 | 2.905 |
10:01 ET | 6879 | 2.9 |
10:03 ET | 1553 | 2.885 |
10:06 ET | 2318 | 2.895 |
10:08 ET | 5142 | 2.885 |
10:10 ET | 17281 | 2.865 |
10:12 ET | 4105 | 2.875 |
10:14 ET | 1100 | 2.87 |
10:15 ET | 3677 | 2.87 |
10:17 ET | 5749 | 2.86 |
10:19 ET | 10970 | 2.855 |
10:21 ET | 9659 | 2.8599 |
10:24 ET | 3580 | 2.85 |
10:26 ET | 4848 | 2.87 |
10:28 ET | 8287 | 2.87 |
10:30 ET | 4129 | 2.8759 |
10:32 ET | 126 | 2.875 |
10:33 ET | 1400 | 2.87 |
10:35 ET | 5375 | 2.885 |
10:37 ET | 451 | 2.8825 |
10:39 ET | 5891 | 2.87 |
10:42 ET | 100 | 2.87 |
10:44 ET | 902 | 2.87 |
10:46 ET | 5094 | 2.85 |
10:48 ET | 355 | 2.855 |
10:50 ET | 6730 | 2.855 |
10:51 ET | 3791 | 2.85 |
10:53 ET | 449 | 2.855 |
10:55 ET | 600 | 2.85 |
10:57 ET | 210 | 2.855 |
11:00 ET | 1508 | 2.855 |
11:02 ET | 500 | 2.855 |
11:04 ET | 1000 | 2.855 |
11:06 ET | 2356 | 2.855 |
11:08 ET | 10198 | 2.865 |
11:09 ET | 600 | 2.86 |
11:11 ET | 6249 | 2.86 |
11:13 ET | 600 | 2.86 |
11:15 ET | 1000 | 2.86 |
11:18 ET | 1756 | 2.86 |
11:20 ET | 7919 | 2.87 |
11:22 ET | 1401 | 2.87 |
11:24 ET | 1647 | 2.87 |
11:26 ET | 6435 | 2.875 |
11:27 ET | 3377 | 2.87 |
11:29 ET | 5189 | 2.885 |
11:31 ET | 825 | 2.88 |
11:33 ET | 4747 | 2.875 |
11:36 ET | 1833 | 2.87 |
11:38 ET | 3949 | 2.89 |
11:40 ET | 1834 | 2.9 |
11:42 ET | 800 | 2.895 |
11:44 ET | 2510 | 2.9 |
11:45 ET | 1705 | 2.895 |
11:47 ET | 1200 | 2.89 |
11:49 ET | 2578 | 2.895 |
11:51 ET | 8812 | 2.895 |
11:54 ET | 1246 | 2.89 |
11:56 ET | 3686 | 2.88 |
11:58 ET | 24693 | 2.905 |
12:00 ET | 300 | 2.905 |
12:02 ET | 500 | 2.905 |
12:03 ET | 10243 | 2.93 |
12:05 ET | 24840 | 2.925 |
12:07 ET | 800 | 2.925 |
12:09 ET | 7185 | 2.94 |
12:12 ET | 2740 | 2.95 |
12:14 ET | 9188 | 2.93 |
12:16 ET | 1343 | 2.925 |
12:18 ET | 857 | 2.925 |
12:20 ET | 1769 | 2.92 |
12:21 ET | 6400 | 2.92 |
12:23 ET | 400 | 2.92 |
12:25 ET | 500 | 2.92 |
12:27 ET | 11262 | 2.93 |
12:30 ET | 600 | 2.935 |
12:32 ET | 470 | 2.93 |
12:34 ET | 1380 | 2.93 |
12:36 ET | 3687 | 2.92 |
12:38 ET | 400 | 2.92 |
12:39 ET | 300 | 2.92 |
12:41 ET | 200 | 2.92 |
12:43 ET | 4406 | 2.915 |
12:45 ET | 400 | 2.91 |
12:48 ET | 500 | 2.91 |
12:50 ET | 600 | 2.915 |
12:52 ET | 300 | 2.915 |
12:54 ET | 300 | 2.915 |
12:56 ET | 8891 | 2.92 |
12:57 ET | 6101 | 2.92 |
12:59 ET | 500 | 2.92 |
01:01 ET | 7214 | 2.9 |
01:03 ET | 4527 | 2.895 |
01:06 ET | 400 | 2.895 |
01:08 ET | 800 | 2.89 |
01:10 ET | 400 | 2.89 |
01:12 ET | 800 | 2.89 |
01:14 ET | 400 | 2.89 |
01:15 ET | 400 | 2.9 |
01:17 ET | 700 | 2.895 |
01:19 ET | 18874 | 2.91 |
01:21 ET | 400 | 2.905 |
01:24 ET | 400 | 2.91 |
01:26 ET | 700 | 2.91 |
01:28 ET | 1350 | 2.91 |
01:30 ET | 12794 | 2.925 |
01:32 ET | 700 | 2.925 |
01:33 ET | 600 | 2.925 |
01:35 ET | 10488 | 2.9 |
01:37 ET | 11010 | 2.9 |
01:39 ET | 5365 | 2.905 |
01:42 ET | 7408 | 2.905 |
01:44 ET | 1305 | 2.905 |
01:46 ET | 16446 | 2.915 |
01:48 ET | 22028 | 2.93 |
01:50 ET | 2916 | 2.925 |
01:51 ET | 5147 | 2.94 |
01:53 ET | 13108 | 2.94 |
01:55 ET | 48891 | 2.93 |
01:57 ET | 700 | 2.935 |
02:00 ET | 1746 | 2.935 |
02:02 ET | 2000 | 2.93 |
02:04 ET | 3325 | 2.93 |
02:06 ET | 2000 | 2.925 |
02:08 ET | 2200 | 2.925 |
02:09 ET | 6016 | 2.93 |
02:11 ET | 100 | 2.93 |
02:13 ET | 101 | 2.935 |
02:15 ET | 910 | 2.94 |
02:18 ET | 4076 | 2.945 |
02:20 ET | 500 | 2.95 |
02:22 ET | 9883 | 2.935 |
02:24 ET | 1547 | 2.936 |
02:26 ET | 4657 | 2.92 |
02:29 ET | 9618 | 2.91 |
02:31 ET | 5047 | 2.9 |
02:33 ET | 5431 | 2.9 |
02:36 ET | 1571 | 2.9 |
02:38 ET | 3323 | 2.9 |
02:40 ET | 1100 | 2.9 |
02:42 ET | 6915 | 2.895 |
02:44 ET | 13473 | 2.9097 |
02:45 ET | 1100 | 2.9 |
02:47 ET | 7374 | 2.895 |
02:49 ET | 26883 | 2.9 |
02:51 ET | 2394 | 2.91 |
02:54 ET | 12178 | 2.915 |
02:56 ET | 3912 | 2.92 |
02:58 ET | 1792 | 2.93 |
03:00 ET | 3949 | 2.925 |
03:02 ET | 8407 | 2.925 |
03:03 ET | 9709 | 2.93 |
03:05 ET | 1000 | 2.925 |
03:07 ET | 7500 | 2.93 |
03:09 ET | 25774 | 2.92 |
03:12 ET | 1440 | 2.9225 |
03:14 ET | 1500 | 2.925 |
03:16 ET | 2117 | 2.92 |
03:18 ET | 1500 | 2.93 |
03:20 ET | 6315 | 2.92 |
03:21 ET | 13206 | 2.95 |
03:23 ET | 4352 | 2.96 |
03:25 ET | 1235 | 2.96 |
03:27 ET | 896 | 2.955 |
03:30 ET | 3400 | 2.96 |
03:32 ET | 2809 | 2.955 |
03:34 ET | 5372 | 2.955 |
03:36 ET | 6047 | 2.96 |
03:38 ET | 17426 | 2.94 |
03:39 ET | 2400 | 2.945 |
03:41 ET | 17292 | 2.955 |
03:43 ET | 6186 | 2.955 |
03:45 ET | 1751 | 2.95 |
03:48 ET | 16661 | 2.945 |
03:50 ET | 12239 | 2.95 |
03:52 ET | 5781 | 2.955 |
03:54 ET | 37373 | 2.94 |
03:56 ET | 7864 | 2.945 |
03:57 ET | 37894 | 2.94 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 731.6M | -9.3x | --- |
Longboard Pharmaceuticals Inc | 725.5M | -8.1x | --- |
GH Research PLC | 746.1M | -19.3x | --- |
CARGO Therapeutics Inc | 703.6M | -6.2x | --- |
Lyell Immunopharma Inc | 701.1M | -2.8x | --- |
Viridian Therapeutics Inc | 778.0M | -2.7x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $731.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.40 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -9.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.